Patidegib - PellePharm

Drug Profile

Patidegib - PellePharm

Alternative Names: FIN-5; IPI-926; Patidegib topical gel - PellePharm; Patidegib-hydrochloride; Saridegib; Saridegib-hydrochloride

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Infinity Pharmaceuticals; PellePharm
  • Class Antineoplastics; Small molecules; Veratrum alkaloids
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chondrosarcoma; Basal cell nevus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Basal cell nevus syndrome
  • Discontinued Chondrosarcoma; Head and neck cancer; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 20 Nov 2017 Patidegib receives Breakthrough Therapy status for Basal Cell Nevus Syndrome in USA
  • 20 Nov 2017 Patidegib receives Orphan Drug status for Basal Cell Nevus Syndrome in USA
  • 20 Nov 2017 PellePharm plans a phase III trial in Basal Cell Nevus Syndrome in USA in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top